<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03335371</url>
  </required_header>
  <id_info>
    <org_study_id>TTP399-203</org_study_id>
    <secondary_id>JDRF#2-IND-2018-500</secondary_id>
    <nct_id>NCT03335371</nct_id>
  </id_info>
  <brief_title>Evaluation of TTP399 in Patients With Type 1 Diabetes</brief_title>
  <acronym>SimpliciT1</acronym>
  <official_title>A Multi-Center, Randomized, Double-Blind, Parallel-Group, Multiple-Dose, Adaptive Study Assessing the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of TTP399 in With Adult Patients Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>vTv Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>vTv Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of TTP399 in Type 1
      diabetics. This study will be in 2 phases: phase 1 will evaluate the safety of different
      TTP399 dosage regimens over 1 week of daily dosing. Phase 2 will evaluate the safety and
      efficacy of a TTP399 dosing regimen over 12 weeks of daily dosing.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 25, 2017</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c from baseline at 12 weeks</measure>
    <time_frame>Day 1 to Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Day 1 to Week 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time in target glycemic range (70-180 mg/dL)</measure>
    <time_frame>Day 1 to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time in hyperglycemic range (Level 1 &gt; 180 mg/dL, Level 2 (&gt;250 mg/dL)</measure>
    <time_frame>Day 1 to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time in hypoglycemic range (Level 1 &lt; 70 mg/dL, Level 2 &lt; 54 mg/dL)</measure>
    <time_frame>Day 1 to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in total daily insulin dose</measure>
    <time_frame>Day 1 to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of meal time bolus insulin</measure>
    <time_frame>Day 1 to Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>TTP399 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TTP399</intervention_name>
    <description>Part 1: Participants will receive TTP399 administered orally up to 1200 mg taken once daily for 7 days</description>
    <arm_group_label>TTP399 400 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TTP399</intervention_name>
    <description>Part 2: Participants will receive TTP399 administered orally dose TBD for 12 weeks</description>
    <arm_group_label>TTP399 400 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Part 2: Participants will receive Placebo oral tablets for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  People diagnosed with T1DM, confirmed diagnosis prior to 40 years of age and a
             diagnosed for minimum of 1 year.

          -  Type 1 diabetics using either continuous subcutaneous insulin infusion (with lispro or
             aspart) or multiple daily doses of insulin

          -  Willing to use adequate contraception

          -  No major surgeries or significant injuries within the past year and without an active
             infection.

        Exclusion Criteria:

          -  Diagnosis of T2DM, severely uncontrolled T1DM, maturity-onset diabetes of the young,
             insulin-requiring T2DM, other unusual or rare forms of diabetes mellitus, diabetes
             resulting from a secondary disease

          -  Receipt of an investigational product within 30 days of the Screening Visit (including
             previous treatment with TTP399) or any therapeutic protein or antibody within 90 days
             prior to Screening Visit.

          -  Living in the same household or related to another participant in this study.

          -  Hypoglycemia unawareness

          -  Two severe episodes of hypoglycemia that required assistance by a third party within 3
             months of Screening Visit

          -  Use of antidiabetic medications other than insulin 3 months prior to Screening Visit,
             systemic corticosteroids 1 month prior to Screening Visit, weight loss medication 2
             weeks prior to Screening Visit, and antipsychotic medications 3 months prior to
             Screening Visit.

          -  Participation in any formal weight loss program or contemplating such therapy during
             the trial.

          -  Recent history of use of non-prescribed controlled substances or illicit drugs.

          -  Current alcoholism or a history of excessive alcohol consumption within 2 years prior
             to screening

          -  History or presence of symptomatic autonomic neuropathy or chronic gastrointestinal
             disease.

          -  Personal history of long QT syndrome.

          -  Blood donation of approximately 1 pint (500 mL) within 8 weeks before Screening Visit

          -  History of hemolytic anemia or chronic transfusion requirement.

          -  History of cancer, other than non-melanoma skin cancer or uterine cervical cancer that
             required therapy in the past 5 years.

          -  Breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carmen Valcarce, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>vTv Therapeutics, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Freeman, Ph.D.</last_name>
    <phone>(336) 841-0300</phone>
    <phone_ext>120</phone_ext>
    <email>clinicaltrials@vtvtherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Site 01</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27517</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2017</study_first_submitted>
  <study_first_submitted_qc>November 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2017</study_first_posted>
  <last_update_submitted>November 3, 2017</last_update_submitted>
  <last_update_submitted_qc>November 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

